Day: August 20, 2025

The Investment is part of BrainsWay’s ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has entered into a strategic equity financing agreement with Axis Management Company, Inc. (“Axis Integrated Mental Health” or “Axis”), a management services organization servicing several mental health clinics in Colorado. Under the terms of the agreement, BrainsWay will invest $2.3 million initially, and an additional potential $1 million milestone-based investment, for a minority...

BEIJING, Aug. 20, 2025 (GLOBE NEWSWIRE) — KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HKEX: 2076), a leading online recruitment platform in China, today announced the upsizing and extension of its share repurchase program. As previously announced, the Company established a share repurchase program on August 29, 2024, whereby the Company was authorized to repurchase up to US$150 million of its shares (including in the form of American depositary shares (“ADS”)) for a 12-month period. On August 20, 2025, the Company’s board of directors approved amendments to its existing share repurchase program, extending the program for a 12-month period through August 28, 2026 and authorizing repurchases of up to US$250 million of the Company’s shares (including ADSs) during the extended 12-month period. Safe Harbor Statement This...

BEIJING, Aug. 20, 2025 (GLOBE NEWSWIRE) — KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HKEX: 2076), a leading online recruitment platform in China, today announced that Ms. Mengyuan Dong has resigned as an independent non-executive director of the Company in order to devote more time to her other personal business commitments, effective on August 20, 2025. In addition, with effect from August 20, 2025, Ms. Hongyu Liu, an independent non-executive director and a member of the nomination committee has been appointed as the chairman of the audit committee and a member of the corporate governance committee. Mr. Yan Li, an independent non-executive director, the chairman of the nomination committee, the chairman of the corporate governance committee, and a member of the audit committee, has been appointed as a member...

Orders mark milestone for Gilat’s linefit ESA strategy, driving in-flight connectivity expansion PETAH TIKVA, Israel, Aug. 20, 2025 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that its Commercial Division has been awarded more than $60 million in orders from a leading satellite operator for its Stellar Blu ESA Sidewinder in-flight connectivity terminals. Deliveries are expected in the next 12 months. These orders, for hundreds of additional Sidewinder ESA terminals, support new airline fleet awards in retrofit and the first production run of Sidewinders for the eventual OEM linefit terminal for Boeing. “The Stellar Blu Sidewinder ESA is redefining airborne connectivity with the performance and flexibility...

DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1×1 meetings at the 2025 Wells Fargo Healthcare Conference being held September 3-5, 2025 in Boston, MA. To schedule a 1×1 meeting with the Company, please contact your Wells Fargo institutional sales representative. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine...

BROOKFIELD, NEWS, Aug. 20, 2025 (GLOBE NEWSWIRE) — Brookfield Corporation (TSX: BN, NYSE: BN) (“Brookfield” or “the Company”) today announced it has received approval from the Toronto Stock Exchange (“TSX”) for the renewal of its normal course issuer bid to purchase up to 10% of the public float of each series of the Company’s outstanding Class A Preference Shares that are listed on the TSX (the “Preferred Shares”). Purchases under the bid will be made on the open market through the facilities of the TSX and/or alternative Canadian trading systems. The period of the normal course issuer bid will extend from August 22, 2025 to August 21, 2026, or an earlier date should Brookfield complete its purchases. Brookfield will pay the market price at the time of acquisition for any Preferred Shares purchased or such other price as may be...